Vertex Pharmaceuticals Incorporated company logo

# RNN 1st Gen Model Vertex Pharmaceuticals Incorporated Pharmaceutical preparations

Prediction models:
RNN 1st Gen RNN 2nd Gen
Subscribe >> Deal exit on
May 3, 2018
69.09% successful of 55 deals
$ 168.16 Last close price
at 18-apr-2019

VRTX

Model's trade recommendations 0.40% Return for period

⁣

⁣ 3.16% Annual return

⁣

⁣ $38.09B Market Cap

⁣

⁣ β 1.44  

⁣

⁣

VRTX

Model (following trade recommendations)

VRTX

Underlying stock

S&P 500

Index
Return for period 0.40%
⁣ -7.37%
⁣ 1.78%
52wk return 27.54%
⁣ 5.40%
⁣ 16.82%
52wk Range —
⁣ 145.72—194.70
⁣ 2000.54—2399.63
Sortino ratio 0.30
⁣
⁣
Sharpe ratio 0.25
⁣
⁣
Norm. RMSE 1.06%
⁣
⁣
Downside risk 17.78%
⁣
⁣
Volatility 0.00%
⁣
⁣
  • STRONG BUY Analysts consensus recommendation

Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious diseases.

Industry sector: Medical

Sector classification: Pharmaceutical preparations

Deep Learning based analysis and prediction model for Vertex Pharmaceuticals Incorporated (VRTX) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.

Model is in the production pipeline since Sept. 30, 2015.

Market data for VRTX model training are being downloaded from the Quandl premium datasets on a daily basis.

Model is being retrained on a daily basis.

Float 250M
P/E 124.56
Shares Outstanding 255M
% Held by Insiders 1.80%
% Held by Institutions 94.80%
EPS (last reported FY) $0.80
EPS (last reported Q) $0.54
EPS, estimated (last reported Q) $0.28
Total revenues $2 B
Net income $0 B